SDHB mutated paraganglioma imitating thyroid tumor: A case report and review of literature

Abstract

Paragangliomas of the head and neck are uncommon tumors arising from parasympathetic ganglia. Paragangliomas are mostly asymptomatic and may manifest as palpable mass of neck. The morphologic features are non-specific and comparable to the other neuroendocrine tumors. Most of hereditary cases are associated with alterations in genes of succinate dehydrogenase (SDH). SDHA and SDHB immunohistochemistry is considered as reliable screening method to detect tumors with genetical alterations. Of note, SDHB mutated paragangliomas have the highest risk of local recurrence, distant metastasis and the development of other tumor phenotypes, which are associated with mutation. Therefore, active surveillance of patients and early surgical treatment are essential. In contrast, SDHB mutated head and neck paragangliomas was considered as completely benign tumors, although, the latest literature describes more controversial cases, which may increase awareness. Here, we present a rare case of 21 years old female with asymptomatic neck paraganglioma, which was unexpectedly diagnosed after pathological and immunohistochemical testing of removed thyroid gland and showed unusual immunohistochemical variation for SDH mutation.

Keywords

Paraganglioma / Neuroendocrine tumor / Neck / SDH / Immunohistochemistry

CONFLICTS OF INTEREST DISCLOSURE

The authors declare that they have no competing interest.

References

[1] Williams MD. Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics. Head Neck Pathol. 2017 Sep; 11(3): 278-87. PMid:28321772. https://doi.org/10.1007/s12105-017-0803-4

[2] Yu X, Wang Y, Wang P, et al. Primary thyroid paraganglioma mimicking medullary thyroid carcinoma: A case report. Oncol Lett. 2015 Aug; 10(2): 1000-2. PMid:26622613. https://doi.org/10.3892/ol.2015.3292

[3] Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018 Jan; 72(1): 106-16. PMid:29239034. https://doi.org/10.1111/his.13277

[4] Aydoğan Bİ, Dizbay Sak S, Güllü S. Cervical Paraganglioma Mimicking Thyroid Nodule: A Rare Clinical Case. Case Rep Endocrinol [Internet]. 2016; 2016. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811066/

[5] Kim B, Yoo Y, Lee J, et al. Pitfalls of Frozen Section Diagnosis for Paraganglioma: A Clinicopathologic Analysis and Review of the Literature. Int J Surg Pathol. 2018 May; 26(3): 213-20.

[6] Lloyd RV, Osamura RY, Kloppel G, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARS Press; 2017.

[7] Fishbein L. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis and Treatment. Hematol Oncol Clin North Am. 2016 Feb; 30(1): 135-50. PMid:26614373.

[8] Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012 Jun; 44(4): 285-92. PMid:22544211. https://doi.org/10.1097/PAT.0b013e3283539932

[9] Barletta JA, Hornick JL.Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol. 2012 Jul; 19(4): 193-203. PMid:22692282. https://doi.org/10.1097/PAP.0b013e31825c6bc6

[10] Persu A, Hamoir M, Grégoire V, et al. High prevalence of SDHB mutations in head and neck paraganglioma in Belgium. J Hypertens. 2008 Jul; 26(7): 1395-401.

[11] Rijken JA, Niemeijer ND, Leemans CR, et al. Nationwide study of patients with head and neck paragangliomas carrying SDHB germline mutations. BJS Open. 2018 Apr; 2(2): 62-9.

[12] Ohtake M, Tateishi K, Murata H, et al. Succinate Dehydrogenase B Subunit-Negative Jugular Foramen Paraganglioma Manifesting Malignant Progression with Pseudohypoxia-Related Atypical Uptake of [18F]-Fluoro-2-Deoxy-d-Glucose:A Case Report. World Neurosurg. 2018 Jun; 114: 47-52. PMid:29510284. https://doi.org/10.1016/j.wneu.2018.02.147

[13] Andrici J, Gill AJ, Hornick JL.Next generation immunohistochemistry: Emerging substitutes to genetic testing? Semin Diagn Pathol. 2018 May; 35(3): 161-9. PMid:28662997. https://doi.org/10.1053/j.semdp.2017.05.004

[14] Udager AM, Magers MJ, Goerke DM, et al. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2018 Jan; 71: 47-54.

[15] Schmit GD, Gorman B, van Heerden JA, et al. Inferior laryngeal paraganglioma mimicking a primary thyroid tumor. Endocr Pract. 2006 Aug; 12(4): 432-5. PMid:16901801. https://doi.org/10.4158/EP.12.4.432

[16] Yu BH, Sheng WQ, Wang J. Primary paraganglioma of thyroid gland: a clinicopathologic and immunohistochemical analysis of three cases with a review of the literature. Head Neck Pathol. 2013 Dec; 7(4): 373-80. PMid:23943066. https://doi.org/10.1007/s12105-013-0467-7

[17] Nguyen NA, Peter I, Levay B, et al. Thyroid gland paraganglioma: report of a case and review of the literature. Int J Clin Exp Med. 2017; 10(12): 16703-16708.

[18] Bockhorn M, Sheu SY, Frilling A, et al. Paraganglioma-like medullary thyroid carcinoma: a rare entity. Thyroid. 2005 Dec; 15(12): 1363-7. PMid:16405409. https://doi.org/10.1089/thy.2005.15.1363

[19] Yano Y, Nagahama M, Sugino K, et al. Paraganglioma of the thyroid: report of a male case with ultrasonographic imagings, cytologic, histologic, and immunohistochemical features. Thyroid. 2007 Jun; 17(6): 575-8. PMid:17614779. https://doi.org/10.1089/thy.2006.0284

[20] Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014 Jun; 21(3): 405-14.

[21] Nicolas M, Dahia P. Predictors of outcome in phaeochromocytomas and paragangliomas. F1000Res [Internet]. 2017 Dec 21; 6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749134/

[22] Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014 Feb; 14(2): 108-19. PMid:24442145. https://doi.org/10.1038/nrc3648

[23] Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011 Sep; 96(9): E1472-1476.

[24] Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010 Jun; 41(6): 805-14.

[25] Santi R, Rapizzi E, Canu L, et al. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. Anticancer Res. 2017; 37(2): 805-12. PMid:28179334. https://doi.org/10.21873/anticanres.11381

[26] Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002 Feb 1; 94(3): 730-7.

[27] Sethi RV, Sethi RKV, Herr MW, et al. Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators. Am J Otolaryngol. 2013 Oct; 34(5): 431-8. PMid:23642313. https://doi.org/10.1016/j.amjoto.2013.03.010

[28] Ellis RJ, Patel D, Prodanov T, et al. The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg. 2014 Jul; 260(1): 158-62. PMid:24169168. https://doi.org/10.1097/SLA.0000000000000283

[29] Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun; 99(6): 1915-42.